Cover Image

Comparative evaluation of 6-fluoro-3-(piperidin-4-yl) benzo[d] isoxazole derivatives and atypical antipsychotics for their anti-diabetic properties

Sharath Chandra S.P., Sathisha K. R., Puneeth H. R., Sharada A. C.*


Atypical antipsychotics used to treat psychotic disorders are known to be associated with extrapyramidal side effects when chronically administered. However there is also evidence of other metabolic side effects which includes type II diabetes mellitus. In the present study we have investigated the anti-diabetic properties of standard antipsychotic resperidone and synthesized molecules S1-S4, which showed significant antipsychotic properties in earlier studies. Studies were performed for α amylase inhibition, α glucosidase inhibition, sucrose inhibition, glucose estimation by GOD-POD method by in vitro gluconeogenesis analysis. In the all the studies performed we observed significant results for synthesized molecules S2 and S4 compared to atypical antipsychotic resperidone. Thus the study concludes that the synthesized molecules have fewer tendencies to cause type II diabetes mellitus when compared to atypical antipsychotic drug.


α Amylase; Antipsychotics; Diabetes mellitus; GOD-POD; Gluconeogenesis

Full Text:



Kane JM and JM Smith. Tardive dyskinesia: prevalence and risk factors. Arch. Gen. Psychiatry.1982; 39, 473-481.

Newcomer JW. Second-generation (atypical) antipsychotics and metabolic effects: a comprehensive literature review. CNS Drugs 2005; 19 Suppl 1: 1-93

Spoelstra JA, Stolk RP, Cohen D, Klungel OH, Erkens JA, Leufkens HG, Grobbee DE. An tipsy choric drugs may worsen metabolic control in type 2 diabetes mellitus. J Clin Psychiatry. 2004; 65(5):674-8.

Ryan MC, Collins P, Thakore JH. Impaired fasting glucose tolerance in firstepisode, drug-naive patients with schizophrenia. Am J Psychiatry 2003; 160:284- 9.

Brunton LL, Chabner B, Knollmann BC, eds. Goodman & Gilman's The Pharmacological Basis of Therapeutics (12th ed.). New York: McGraw-Hill. ISBN.2011; 978-0-07-162442-8.

Weston-Green K, Huang XF, Deng C, Chang, Alice Y. W, ed. "Alterations to melanocortinergic, GABAergic and cannabinoid neurotransmission associated with olanzapine-induced weight gain". PLoS ONE 2012; 7 (3): e33548.

Sharath Chandra S P, Raghava B, Sharada A C ; Synthesis, Characterisation, Molecular property prediction and Antipsychotic activity of Novel 6-fluoro-3-(piperidin-4-yl) benzo[d]isoxazole Derivatives. International Journal of Pharmaceutical Sciences Review and Research, 2014; eISSN: 0976-044X.

Sharath Chandra S P, Sharada A C: Effects Of 6-Fluoro-3-(Piperidin-4-Yl) Benzo [D]Isoxazole Derivatives On Dopamine-D2 And Serotonin-5ht2 Receptors Mediated Behaviours In Albino Mice And Other Antipsychotic Studies. Int. Res.J. Pharm. 2014; 5(10); 806-9.

Bharathkumar H, Sundaram MS, Jagadish S, Paricharak S, Hemshekhar M, Mason D, Kemparaju K, Girish KS, Basappa, Bender A, Rangappa KS. Novel Benzoxazine-Based Aglycones Block Glucose Uptake In Vivo by Inhibiting Glycosidases. 2014; 9(7) e102759.

Puneeth H R, Sharada A C. Antioxidant and Hypoglycemic effects of curcumin pyrazole derivatives. Int J Pharm and Pharmaceu Sci. 2015; 7 (4) 244-9.

Roobol A, Alleyne GAO. A study of stabilization of gluconeogenic activity in rat liver slices by calcium and manganese ions. Biochem J 1972; 129:231-9.

Rahimi R, Nikfar S, Larijani B, Abdollahi M. A review on the antioxidants in the management of diabetes and its complications. Biomed Pharmacother 2005; 59: 365-73.

Koller EA, Doraiswamy PM. "Olanzapine-associated diabetes mellitus". Pharmacotherapy 2002; 22 (7): 841–52

Mayur B, Sandesh S, Shruti S, Sung-Yum S. Antioxidant and α- glucosidase inhibitory properties of Carpesium abrotanoides L. J Med Plant Res 2010; 4: 1547-53.

Mccue P, Shetty K. Inhibitory effects of rosmarinic acid extracts on porcine pancreatic amylase in vitro. Asian Pac J Clin Nutr 2004; 13: 101-6.



  • There are currently no refbacks.

Copyright (c) 2015 International Journal of Bioassays

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.

International Journal of Bioassays is a member of the Publishers International Linking Association, Inc. (PILA), CROSSREF and CROSSMARK (USA). Digital Object Identifier (DOI) will be assigned to all its published content.